Evaluation of mHealth for Serious Mental Illness
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18 years or older
- Owns an Android or iPhone smartphone with WiFi or 3G/4G capabilities (required for data transmission)
- Has diagnosis of Schizophrenia, Schizoaffective Disorder, Bipolar Disorder or Major Depression
- English speaker
Exclusion Criteria:
- Does not live in the U.S.
- Has already participated in the study
- Unavailable for 60 days
- Currently incarcerated or hospitalized
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Active
Instructed to download the app and use the app daily for 30 days.
|
The application consists of content areas focused on mental health.
|
|
ACTIVE_COMPARATOR: Waitlist Control
Waitlist control.
|
Waitlist control
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Depressive Symptoms
Time Frame: Baseline, 30 days, 60 days
|
The Beck Depression Inventory is a self-reported 21-item inventory, scores range from 0-63 and items are summed to compute the total score.
A higher score represents more depressive symptoms.
|
Baseline, 30 days, 60 days
|
|
Change in Paranoid Thinking
Time Frame: Baseline, 30 days, 60 days
|
The Green Paranoid Thoughts Scale Parts A & B is a 32-item scale, the total score is summed with a range of 16-80.
A higher score represents more symptoms of paranoid thinking.
|
Baseline, 30 days, 60 days
|
|
Change in Anxiety Symptoms
Time Frame: Baseline, 30 days, 60 days
|
The Generalized Anxiety Disorder 7-item Scale is summed with a total score range of 0-21.
Higher scores represent more symptoms of anxiety.
|
Baseline, 30 days, 60 days
|
|
Change in Psychotic Symptoms
Time Frame: Baseline, 30 days, 60 days
|
The Hamilton Program for Schizophrenia Voices Questionnaire is a 13-item questionnaire, 9 of the items are scored 0 (least severe or impairing) to 4 (most severe).
The total score is intended to indicate the overall severity of psychotic symptoms.
Total score range is 0-36.
The remaining 4 items are intended to assess qualitative aspects.
|
Baseline, 30 days, 60 days
|
|
Participant Acceptability
Time Frame: 30 days
|
Participant Acceptability/Usability Ratings Scale is a 26-item scale measuring participant-rated acceptability of the intervention.
Participants rate statements on a scale of Disagree (0), Neutral (1), or Agree (2).
Items are summed to create a total score and a higher total score indicates greater acceptability.
|
30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- STUDY00006898
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
NCT07369401Not yet recruiting
-
NCT01190254CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT07184619Recruiting
-
NCT01190267CompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
NCT05944510CompletedTreatment Resistant Schizophrenia
-
NCT07626034Not yet recruiting
Clinical Trials on Smartphone App
-
NCT05169151WithdrawnMalignant Solid Neoplasm | Sarcoma | Hodgkin Lymphoma | Non-Hodgkin Lymphoma | Central Nervous System Neoplasm
-
NCT03996109Active, not recruitingAdolescent Behavior | Healthy Lifestyle
-
NCT04409236Active, not recruitingMalignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm
-
NCT02497755Completed
-
NCT07165561CompletedSuicidal Ideation | Suicidal Behavior | Coping Behavior
-
NCT04896593CompletedSuicidal Ideation | Suicide, Attempted
-
NCT02756949CompletedHIV Infections | Antiretroviral Therapy | Patient Compliance | Viral Load | Cell Phone
-
NCT03114293UnknownMultiple Sclerosis, Chronic Progressive